CytoTest Inc. is a world leading biotechnology company providing high quality, innovative and affordable molecular cytogenetics products and services. Our US headquarters are located in suburban Washington, DC, in Maryland, close to the National Institutes of Health (NIH), one of the world's leading centers for biological research. Our proximity to and interaction with NIH, along with spirited connections with our other strategic partners in the academic, biotechnology and clinical communities enables us to stay at the forefront of diagnostic medicine and closely monitor trends and developments in molecular cytogenetics. It also allows us to take a uniquely proactive approach to the development and validation of tests in response to new and anticipated needs of research and clinical pathology.

 
^{CytoTest Maryland Biotech Park IVD GMP Facility}

Originally specializing in the design and production of DNA fluorescence in situ hybridization (FISH) probes, CytoTest has expanded its offerings to include Next Generation Sequencing (NGS) technology products. FISH, a powerful technique for detecting presence or absence, location, integrity and amount of genomic sequences in cells and tissue samples, has been a cornerstone cytogenetic research tool since the 1980s and is a gold standard technique in diagnosing chromosomal abnormalities. Building on this foundation, we have embraced NGS to further enhance our capabilities in genomic analysis, enabling comprehensive genetic profiling that supports precision medicine, complex disease research, and advanced diagnostic applications.

We are also advancing an innovative technology platform utilizing CRISPR technology to detect cancer biomarkers. This groundbreaking approach promises a more cost-effective alternative to traditional cancer genetic diagnostics, significantly improving accessibility and affordability. By harnessing the precision of CRISPR, we aim to revolutionize cancer detection, providing earlier and more accurate diagnoses, ultimately enhancing patient outcomes and advancing the field of oncology.

Our product pipeline now encompasses over 1,000 different FISH probes and NGS panels targeting a wide array of applications, from oncology and personalized medicine to prenatal testing and theranostics. We continually expand our offerings through robust internal R&D and by responding to specific customer requests for novel diagnostic tests, particularly in the areas of rare cancers and companion diagnostics for emerging therapies.

CytoTest manufactures products for both research and diagnostic purposes across the globe, adhering to stringent regulatory standards to ensure the highest quality. Our multi-year optimization efforts have resulted in superior products that set industry benchmarks. We stay abreast of scientific advancements and regulatory shifts pertinent to in vitro diagnostics (IVDs) and laboratory developed tests (LDTs), ensuring our solutions meet the latest industry standards.

With a multi-disciplinary team of passionate and dedicated researchers, CytoTest can carry out manufacturing at all scales and is able to offer solutions for a wide range of diagnostic testing needs, from standard reagent production to flexible custom design. We also are forming strategic collaborations to develop molecular diagnostic tests for novel and rare conditions, unfilled diagnostic niches, and for marketing in underserved regions.

At CytoTest Inc., our mission is to transform human genomic discoveries into practical, high-quality diagnostic tools. We are dedicated to advancing the fields of molecular cytogenetics and genomic sequencing, providing cost-effective products, exceptional customer service, and reliable technical support. Our goal is to develop state-of-the-art molecular diagnostics that are not only innovative but also accessible to the global community.